全文获取类型
收费全文 | 10690篇 |
免费 | 725篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 208篇 |
妇产科学 | 54篇 |
基础医学 | 1284篇 |
口腔科学 | 186篇 |
临床医学 | 692篇 |
内科学 | 3001篇 |
皮肤病学 | 331篇 |
神经病学 | 568篇 |
特种医学 | 359篇 |
外科学 | 2005篇 |
综合类 | 42篇 |
一般理论 | 2篇 |
预防医学 | 208篇 |
眼科学 | 156篇 |
药学 | 700篇 |
中国医学 | 15篇 |
肿瘤学 | 1564篇 |
出版年
2023年 | 151篇 |
2022年 | 113篇 |
2021年 | 488篇 |
2020年 | 277篇 |
2019年 | 367篇 |
2018年 | 407篇 |
2017年 | 323篇 |
2016年 | 360篇 |
2015年 | 361篇 |
2014年 | 384篇 |
2013年 | 425篇 |
2012年 | 691篇 |
2011年 | 737篇 |
2010年 | 381篇 |
2009年 | 319篇 |
2008年 | 556篇 |
2007年 | 488篇 |
2006年 | 454篇 |
2005年 | 423篇 |
2004年 | 440篇 |
2003年 | 412篇 |
2002年 | 380篇 |
2001年 | 212篇 |
2000年 | 231篇 |
1999年 | 198篇 |
1998年 | 108篇 |
1997年 | 102篇 |
1996年 | 65篇 |
1995年 | 84篇 |
1994年 | 83篇 |
1993年 | 67篇 |
1992年 | 108篇 |
1991年 | 118篇 |
1990年 | 100篇 |
1989年 | 114篇 |
1988年 | 103篇 |
1987年 | 89篇 |
1986年 | 114篇 |
1985年 | 91篇 |
1984年 | 58篇 |
1983年 | 61篇 |
1982年 | 34篇 |
1979年 | 40篇 |
1978年 | 22篇 |
1977年 | 44篇 |
1975年 | 27篇 |
1972年 | 30篇 |
1971年 | 30篇 |
1970年 | 32篇 |
1969年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Iwasa-Inoue Naomi Nomura Hiroyuki Kataoka Fumio Chiyoda Tatsuyuki Yoshihama Tomoko Nanki Yoshiko Sakai Kensuke Kobayashi Yusuke Yamagami Wataru Morisada Tohru Hirasawa Akira Aoki Daisuke 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(2):441-447
International Journal of Clinical Oncology - This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian,... 相似文献
2.
Yusuke Satoh Hitoshi Kotani Yuichi Iida Takahito Taniura Yoshitomo Notsu Mamoru Harada 《Cancer science》2020,111(7):2248-2258
Myeloid‐derived suppressor cells (MDSCs) play a crucial role in immunosuppression in tumor‐bearing hosts. MDSCs express arginase‐I and indoleamine 2,3‐dioxygenase; they suppress T‐cell function by reducing the levels of l ‐arginine and l ‐tryptophan, respectively. We examined the anticancer effects of supplementation of these amino acids in CT26 colon carcinoma‐bearing mice. Oral supplementation of l ‐arginine or l ‐tryptophan (30 mg/mouse) did not affect tumor growth, whereas oral supplementation of d ‐arginine was lethal. Supplementation of l ‐arginine showed a tendency to augment the efficacy of cyclophosphamide (CP). CP reduced the proportions of granulocytic MDSCs and increased the proportions of monocytic MDSCs in the spleen and tumor tissues of CT26‐bearing mice. l ‐Arginine supplementation alone did not affect the MDSC subsets. CP treatment tended to reduce the plasma levels of l ‐arginine in CT26‐bearing mice and significantly increased the number of tumor‐infiltrating CD8+ T cells. In addition, l ‐arginine supplementation significantly increased the proportions of tumor peptide‐specific CD8+ T cells in draining lymph nodes. Importantly, additional supplementation of l ‐arginine significantly increased the number of cured mice that were treated with CP and anti‐PD‐1 antibody. Totally, l ‐arginine supplementation shows promise for boosting the therapeutic efficacy of chemoimmunotherapy. 相似文献
3.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
4.
Tada Kazuhiro Iwashita Yukio Shiraiwa Ken Uchida Hiroki Oshima Yusuke Sato Yuhki Nakanuma Hiroaki Hirashita Teijiro Masuda Takashi Endo Yuichi Takeuchi Yu Ohta Masayuki Itoh Hiroki Inomata Masafumi 《Cancer chemotherapy and pharmacology》2020,85(2):345-352
Cancer Chemotherapy and Pharmacology - Chemotherapy after hepatectomy for colorectal liver metastasis has not been established, due to the toxic side effects, which are likely related to impaired... 相似文献
5.
Reciprocal expression of trefoil factor‐1 and thyroid transcription factor‐1 in lung adenocarcinomas
6.
7.
Post‐operative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case–controlled study using a Japanese database 下载免费PDF全文
8.
9.
Byoung Chul Cho Busayamas Chewaskulyong Ki Hyeong Lee Arunee Dechaphunkul Virote Sriuranpong Fumio Imamura Naoyuki Nogami Takayasu Kurata Isamu Okamoto Caicun Zhou Ying Cheng Eun Kyung Cho Pei Jye Voon Jong-Seok Lee Helen Mann Matilde Saggese Thanyanan Reungwetwattana Suresh S. Ramalingam Yuichiro Ohe 《Journal of thoracic oncology》2019,14(1):99-106
Introduction
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI–sensitizing mutations.Methods
Eligible Asian patients (enrolled at Asian sites) who were at least 18 years of age (≥20 years in Japan) and had untreated EGFR-mutated advanced NSCLC were randomized 1:1 to receive osimertinib (80 mg, orally once daily) or an SoC EGFR TKI (gefitinib, 250 mg, or erlotinib, 150 mg, orally once daily). The primary end point was investigator-assessed progression-free survival (PFS). The key secondary end points were overall survival, objective response rate, central nervous system efficacy, and safety.Results
The median PFS was 16.5 versus 11.0 months for the osimertinib and SoC EGFR TKI groups, respectively (hazard ratio = 0.54, 95% confidence interval: 0.41–0.72, p < 0.0001). The overall survival data were immature (24% maturity). The objective response rates were 80% for osimertinib and 75% for an SoC EGFR TKI. The median central nervous system PFS was not calculable for the osimertinib group and was 13.8 months for the SoC EGFR TKI group (hazard ratio = 0.55, 95% confidence interval: 0.25–1.17, p = 0.118). Fewer adverse events of grade 3 or higher (40% versus 48%) and fewer adverse events leading to treatment discontinuation (15% versus 21%) were reported with osimertinib versus with an SoC EGFR TKI, respectively.Conclusion
In this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population. 相似文献10.
Marie Ohata Susumu Fujiwara Ai Yoshioka Hiroshi Nagai Shintaro Sugita Nozomi Yamano Yusuke Inoue Chikako Nishigori 《Pediatric dermatology》2019,36(6):997-998
Fibroblastic connective tissue nevus (FCTN) is a benign cutaneous mesenchymal lesion characterized by proliferation of CD34‐positive fibroblastic/myofibroblastic spindle‐shaped cells. We report a case of agminated FCTN on the right lower abdomen of a 1‐year‐old boy. 相似文献